Can FKBP5 rs1360780 and CRHR1 rs110402 variants contribute to early-morning waking?

The hypothalamic-pituitary-adrenal (HPA) axis relies on precise feedback loops to regulate diurnal rhythms, including the transition from sleep to wakefulness. Genetic variations in key regulatory proteins can disrupt this timing, leading to altered cortisol patterns and sleep disturbances.

Mechanistic pathways of HPA axis dysregulation

• Glucocorticoid receptor resistance: The FKBP5 rs1360780 T allele drives elevated expression of the FKBP51 co-chaperone, which decreases glucocorticoid receptor sensitivity and delays the negative feedback termination of the cortisol stress response.
• Altered CRH signaling: The CRHR1 rs110402 variant modulates peak HPA axis reactivity and corticotropin-releasing hormone (CRH) kinetics, directly disturbing the timing and magnitude of the diurnal rhythm.
• Epigenetic interactions: Exposure to early-life adversity or childhood maltreatment interacts synergistically with these genetic variants to alter DNA methylation, further exacerbating glucocorticoid feedback loop dysfunction.

Clinical evidence and sleep implications

• Blunted cortisol awakening response (CAR): Together, these HPA axis alterations flatten the physiological morning cortisol surge, leading to blunted or suboptimal waking cortisol levels.
• Sleep phenotype associations: Although both variants are robustly linked to self-reported insomnia and general sleep disturbances, direct evidence connecting these suboptimal morning cortisol levels specifically to early-morning waking patterns remains partly inferential and lacks extensive validation via objective polysomnographic sleep tracking.

Bottom line

• Polymorphisms in FKBP5 (rs1360780) and CRHR1 (rs110402) impair glucocorticoid feedback dynamics and flatten the cortisol awakening response. While this HPA axis dysregulation is a highly plausible driver of disrupted sleep architecture, direct clinical confirmation linking these specific genotypes to early-morning awakening requires further objective sleep study validation.